Protease inhibitor-containing antiretroviral treatment and tuberculosis: Can rifabutin fill the breach?

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 1, 2012, Pages 6-15

  Loeliger, A ^a   Suthar, A B ^a   Ripin, D ^b   Glaziou, P ^a   O'Brien, M ^b   Renaud Thery, F ^a   Crowley, S ^a   Williams, B ^c   Ridzon, R ^d   Granich, Reuben ^a   Gilks, C ^e  

^a UNAIDS   (Switzerland)

^b CLINTON HEALTH ACCESS INITIATIVE   (United States)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d BILL AND MELINDA GATES FOUNDATION   (United States)

^e UNAIDS India Country Office   (India)

Author keywords

AIDS; Anti tubercular agents; HAART; HIV; Protease inhibitors; Rifabutin; Tuberculosis

Indexed keywords

AMPRENAVIR; CD4 ANTIGEN; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETHAMBUTOL; INDINAVIR; ISONIAZID; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST CONTROL; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LEUKOPENIA; LOWEST INCOME GROUP; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBIOTICS, ANTITUBERCULAR; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COINFECTION; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MYCOBACTERIUM TUBERCULOSIS; RIFABUTIN; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 82455223195     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.10.0626     Document Type: Review

References (77)

1. Joint United Nations Programme on HIV/AIDS. Report on the Global AIDS Epidemic. New York, NY, USA: UNAIDS, 2010. http://www.unaids.org/en/media/ unaids/contentassets/documents/unaidspublication/2010/20101123-globalreport-en. pdf Accessed June 2011.
2. World Health Organization. Global tuberculosis control. WHO/HTM/TB/2010.7. Geneva, Switzerland: WHO, 2010. http: //whqlibdoc.who.int/ publications/2010/9789241564069-eng.pdf Accessed June 2011.
3. Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS 2000; 14: 1985-1991.
4. Miranda A, Morgan M, Jamal L, et al. Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001. PLoS One 2007; 2: e826.
5. Santoro-Lopes G, de Pinho A M, Harrison L H, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002; 34: 543-546. (Pubitemid 34112278)
6. Lawn S D, Myer L, Edwards D, Bekker L G, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009; 23: 1717-1725.
7. World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for PLWH in resource-constrained settings. Geneva, Switzerland: WHO, 2010. http://whqlibdoc.who.int/publications/ 2011/9789241500708-eng.pdf Accessed June 2011.
8. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva, Switzerland: WHO, 2010. http: //whqlibdoc.who.int/publications/2010/ 9789241599764-eng.pdf Accessed June 2011.
9. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 4th ed. WHO/HTM/TB/2009. 420. Geneva, Switzerland: WHO, 2010. http://whqlibdoc.who.int/publications/2010/9789241547833-eng.pdf Accessed June 2011.
10. Abdool Karim S S, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362: 697-706.
11. Blanc F X, Sok T, Laureillard D, et al. Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis. In: XVIII International AIDS Conference. Vienna, Austria, 2010. [Abstract]
12. Abdool Karim S, Naidoo K, Padayatchi N, et al. Optimal timing of ART during TB therapy: findings of the SAPiT trial. In: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 2011. [Abstract]
13. Havlir D, Ive P, Kendall M, et al. International randomized trial of immediate vs early ART in HIV+ patients treated for TB: ACTG 5221 STRIDE Study. In: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA: 2011. [Abstract]
14. Gilks C F, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368: 505-510. (Pubitemid 44142772)
15. World Health Organization. Operational guide for national tuberculosis control programmes on the introduction and use of fixed-dose combination drugs. 2002. WHO/CDS/TB/2002. 308 - WHO/EDM/PAR/2002.6. Geneva, Switzerland: WHO, 2010. http://whqlibdoc.who.int/hq/2002/WHO-CDS-TB-2002.308.pdf Accessed June 2011.
16. Baciewicz A M, Chrisman C R, Finch C K, Self T H. Update on rifampin and rifabutin drug interactions. Am J Med Sci 2008; 335: 126-136. (Pubitemid 351253409)
17. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300: 530-539.
18. Dooley K E, Flexner C, Andrade A S. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. J Infect Dis 2008; 198: 948-961.
19. World Health Organization. Prioritizing second-line antiretroviral drugs for adults and adolescents: a public health approach. Report of a WHO Working Group meeting, 22 May 2007. Geneva, Switzerland: WHO, 2010. http://www.who.int/ hiv/pub/meetingreports/Second-Line-Antiretroviral.pdf Accessed June 2011.
20. Acosta E P, Kendall M A, Gerber J G, et al. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother 2007; 51: 3104-3110. (Pubitemid 350067515)
21. Burger D M, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother 2006; 50: 3336-3342. (Pubitemid 44527507)
22. Mallolas J, Sarasa M, Nomdedeu M, et al. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. HIV Med 2007; 8: 131-134. (Pubitemid 46390850)
23. la Porte C J, Colbers E P, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004; 48: 1553-1560. (Pubitemid 38544359)
24. Nijland H M, L'Homme R F, Rongen G A, et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 2008; 22: 931-935. (Pubitemid 351652243)
25. Rolla V C, da Silva Vieira M A, Pereira Pinto D, et al. Safety, efficacy and pharmacokinetics of ritonavir 400 mg/saquinavir 400 mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis. Clin Drug Investig 2006; 26: 469-479.
26. Onyebujoh P C, Ribeiro I, Whalen C C. Treatment options for HIV-associated tuberculosis. J Infect Dis 2007; 196 (Suppl 1): S35-S45. (Pubitemid 47206083)
27. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353: 1843-1847. (Pubitemid 29251017)
28. Benator D A, Weiner M H, Burman W J, et al. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection. Pharmacotherapy 2007; 27: 793-800. (Pubitemid 46849423)
29. Cato A III, Cavanaugh J, Shi H, Hsu A, Leonard J, Granneman R. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther 1998; 63: 414-421. (Pubitemid 28214964)
30. Gallicano K, Khaliq Y, Carignan G, Tseng A, Walmsley S, Cameron D W. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2001; 70: 149-158. (Pubitemid 32777767)
31. Hamzeh F M, Benson C, Gerber J, et al. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. Clin Pharmacol Ther 2003; 73: 159-169. (Pubitemid 36269667)
32. Kraft W K, McCrea J B, Winchell G A, et al. Indinavir and rifabutin drug interactions in healthy volunteers. J Clin Pharmacol 2004; 44: 305-313. (Pubitemid 38233827)
33. Moyle G J, Buss N E, Goggin T, Snell P, Higgs C, Hawkins D A. Interaction between saquinavir soft-gel and rifabutin in patients infected with HIV. Br J Clin Pharmacol 2002; 54: 178-182. (Pubitemid 35024942)
34. Ford S L, Chen Y C, Lou Y, et al. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. Antimicrob Agents Chemother 2008; 52: 534-538. (Pubitemid 351170825)
35. Agarwala S, Mummaneni V, Randall D, Geraldes M, Stoltz R, O'Mara E. Pharmacokinetic (PK) effect of rifabutin (RIF) on atazanavir (ATV) with and without ritonavir (RTV) in healthy subjects. In: 9th Conference on Retrovirusses and Opportunistic Infections, 24-28 February; Seattle, WA, USA, 2002. [Abstract no 445-W]
36. Bertz R, Hsu A, Lam W, et al. Pharmacokinetic interactions between kaletra (lopinavir/ritonavir or ABT-378/r) and other non-HIV drugs. In: 5th International Congress on Drug Therapy in HIV Infection, 22-26 October, 2000; Glasgow, UK. [Abstract]
37. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Geneva, Switzerland: WHO, 2010. http://whqlibdoc.who.int/publications/2010/9789241500395-eng.pdf Accessed June 2011.
38. Mugyenyi P, Walker A S, Hakim J, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010; 375: 123-131.
39. Hirnschall G, Schwartlander B. Treatment 2.0: catalysing the next phase of scale-up. Lancet 2011; Feb 24. [Epub ahead of print].
40. World Health Organization. WHO model list of essential medicines, 16th list. Geneva, Switzerland: WHO, 2009. http://www.who.int/selection-medicines/ committees/expert/17/sixteenth-adult-list-en.pdf Accessed June 2011.
41. World Health Organization. Essential medicines, definitions. Geneva, Switzerland: WHO, 2008. http://www.who.int/medicines/services/essmedicines-def/ en/ Accessed May 2011.
42. Clinton Health Access Initiative. President Clinton, Pfizer, and Mylan announce new agreements to lower prices of medicines for patients with drug-resistant HIV in developing countries. New York, NY, USA: CHAI, 2009. http://aidsalliance.3cdn.net/3361d31e8019f1447f-ihm6bxsk6.pdf Accessed June 2011.
43. Galarraga O, O'Brien M E, Gutierrez J P, et al. Forecast of demand for antiretroviral drugs in low and middle-income countries: 2007-2008. AIDS 2007; 21 (Suppl 4): S97-S103. (Pubitemid 47051755)
44. Williams B G, Granich R, De Cock K M, Glaziou P, Sharma A, Dye C. Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci USA 2010; 107: 19485-19489.
45. Clinton Health Access Initiative. Antiretroviral price list. New York, NY, USA: CHAI, 2009. http://www.clintonfoundation.org/files/ chaiarvpricelistaugust2009english.pdf Accessed June 2011.
46. World Health Organization. Global price reporting mechanism 2009. Geneva, Switzerland: WHO, 2009. http://www.who.int/hiv/amds/gprm/en/index.html Accessed June 2011.
47. Hong Kong Chest Service/British Medical Research Council. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tubercle Lung Dis 1992; 73: 59-67.
48. Burman W, Benator D, Vernon A, et al. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006; 173: 350-356. (Pubitemid 43209091)
49. Gonzalez-Montaner L J, Natal S, Yongchaiyud P, Olliaro P. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Rifabutin Study Group. Tubercle Lung Dis 1994; 75: 341-347. (Pubitemid 24336530)
50. Li J, Munsiff S S, Driver C R, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis 2005; 41: 83-91. (Pubitemid 40863749)
51. Matteelli A, Olliaro P, Signorini L, et al. Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study. Int J Tuberc Lung Dis 1999; 3: 1043-1046.
52. McGregor M M, Olliaro P, Wolmarans L, et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996; 154: 1462-1467. (Pubitemid 26391198)
53. Narita M, Stambaugh J J, Hollender E S, Jones D, Pitchenik A E, Ashkin D. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis. Clin Infect Dis 2000; 30: 779-783.
54. Nettles R E, Mazo D, Alwood K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 2004; 38: 731-736. (Pubitemid 38333871)
55. Rowinska-Zakrzewska E, Slupek A, Graczyk J, et al. [Preliminary results of rifabutine (ansamycine LM 427) treatment of patients with newly detected and chronic pulmonary tuberculosis and Mycobacterium infections]. Pneumonol Alergol Pol 1992; 60: 81-88. [Polish]
56. Schwander S, Rüsch-Gerdes S, Mateega A, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tubercle Lung Dis 1995; 76: 210-218.
57. Spradling P, Drociuk D, McLaughlin S, et al. Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreak. Clin Infect Dis 2002; 35: 1106-1112. (Pubitemid 35239471)
58. Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005; 40: 1481-1491. (Pubitemid 40628637)
59. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev 2007: CD005159.
60. Nightingale S D, Cameron D W, Gordin F M, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993; 329: 828-833. (Pubitemid 23267209)
61. Centers for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis. Atlanta, GA, USA: CDC, 2007. http://www.cdc.gov/tb/TB-HIV-Drugs/PDF/tbhiv.pdf Accessed June 2011.
62. Australasian Society for HIV Medicine. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2010. http://ashm.org.au/projects/arvguidelines/images/ASHMPublications/pdf/ 201006-arv-guidelines-with-aus-commentary.pdf Accessed June 2011.
63. United States Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents - January 10, 2011. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf Accessed June 2011.
64. Jenny-Avital E R, Joseph K. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Clin Infect Dis 2009; 48: 1471-1474.
65. Boulanger C, Hollender E, Farrell K, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 2009; 49: 1305-1311.
66. Khachi H, O'Connell R, Ladenheim D, Orkin C. Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection. J A ntimicrob Chemother 2009; 64: 871-873.
67. Naiker S, Conolly C, Weisner L, et al. Pharmacokinetic evaluation of different rifabutin dosing strategies in African TB patients on lopinavir/ritonavir-based ART. In: 18th Conference on Retroviruses and Opportunistic Infections, 27 February-2 March; Boston, MA, USA, 2011. [Abstract 650]
68. Stohr W, Back D, Dunn D, et al. Factors influencing lopinavir and atazanavir plasma concentration. J Antimicrob Chemother 2010; 65: 129-137.
69. French National Agency for Research on AIDS and Viral Hepatitis. Pharmacokinetics of rifabutin combined with antiretroviral therapy in patients with TB-HIV co-infection in Vietnam. Paris, France: ANRS, 2011. http://clinicaltrials.gov/ct2/show/NCT00651066 Accessed June 2011.
70. French National Agency for Research on AIDS and Viral Hepatitis. Pharmacokinetics of rifabutin combined with antiretroviral therapy in patients with TB-HIV co-infection in South Africa. Paris, France: ANRS, 2011. http://clinicaltrials.gov/ct2/show/NCT00640887 Accessed June 2011.
71. Harriet Shezi Children's Clinic, Chris Hani Baragwanath Hospital. Dosing, safety and pharmacokinetic profile of rifabutin in children receiving concomitant treatment with kaletra. Johannesburg, South Africa: Chris Hani Baragwanath Hospital, 2011. http://clinicaltrials.gov/ct2/show/NCT01259219 Accessed June 2011.
72. Murphy R, Sunpath H, Nijhawan A, McLellan M, Kuritzkes D. Lopinavir/ritonavir (LPV/r) + 2 nucleoside analogues as second-line ART in protease inhibitor-naive adults in South Africa: outcomes and adverse effects. In: 15th Conference on Retroviruses and Opportunistic Infections, 3-6 February; Boston, MA, USA, 2008. [Abstract #831]
73. Hosseinipour M C, Kumwenda J J, Weigel R, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med 2010; 11: 510-518.
74. Lawn S D, Myer L, Bekker L G, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20: 1605-1612. (Pubitemid 44162402)
75. Lawn S D, Wilkinson R J, Lipman M C, Wood R. Immune reconstitution and 'unmasking' of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008; 177: 680-685. (Pubitemid 351490554)
76. Lawn S D, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19: 2109-2116. (Pubitemid 41668999)
77. Chimbetete C, Kityo C, Munderi P, et al. Immunological response to boosted PI-containing second-line ART after switching for clinical/immunological criteria is comparable to response to first-line in patients with low CD4 cell counts in Africa. In: 15th Conference on Retroviruses and Opportunistic Infections, 3-6 February; Boston, MA, USA, 2008. [Abstract #832]